Cellular Biomedicine's Stock Price Quadruples in Two Months

On Monday, August 18, Dr. William Cao, CEO of Cellular Biomedicine Group will ring the closing bell at NASDAQ to celebrate CBMG's recent listing on the exchange.  CBMG is a US-headquartered biotech that is developing new treatments for degenerative diseases and cancer in China. The NASDAQ event caps a busy two months for CBMG. During that time, the company reported positive data from a trial of its knee arthritis treatment, jettisoned its consulting business, raised $10 million in a private placement, paid $23 million to acquire a China cellular products company – and the company's stock price rose from below $6 to $23. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //